Business
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit
RESEARCH TRIANGLE PARK, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present
About this update from Biocryst Pharmaceuticals, Inc.
[{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused research highlighting the burden of current treatments for HAE on pediatric patients under the age of 12 and their caregivers and perspectives on the importance of HAE treatments. The findings will be presented in posters at the 2025 US HAEA National Summit in Baltimore, which is taking place July 10-13, 2025. “For more than a decade, we have been honored to join the HAE patient community at the US HAEA National Summit. It is an opportunity for us to hear directly from them on their hopes and dreams for a brighter future so we can keep working with them and for them to try to make these dreams a reality. This is what drove us to bring the first oral, once-daily prophylactic therapy for HAE for adults and adolescents and will continue to drive us to try to do even more for this community in the future,” said Jon Stonehouse, president and chief executive officer of BioCryst. BioCryst will present the following three abstracts in a poster session on Friday, July 11 from 12:30-1:30 p.m. ET: Patient Perspectives on the Importance of HAE Treatments; Poster #25Burden of Treatment for Pediatrics Patients (Aged Less Than 12 Years) With Hereditary Angioedema and Their Caregivers; Poster #4HAE Attack Rates in Pediatric Patients 2 to","length":2208,"tagName":"div"}]